Recurrent Islet Cell Carcinoma Completed Phase 1 Trials for Carboplatin (DB00958)

IndicationStatusPhase
DBCOND0028802 (Recurrent Islet Cell Carcinoma)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00004074Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/NeuTreatment